163 related articles for article (PubMed ID: 22520332)
1. A highly soluble matrix metalloproteinase-9 inhibitor for potential treatment of dry eye syndrome.
Mori M; De Lorenzo E; Torre E; Fragai M; Nativi C; Luchinat C; Arcangeli A
Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):289-95. PubMed ID: 22520332
[TBL] [Abstract][Full Text] [Related]
2. [New therapeutic options for dry eye].
Messmer EM
Ophthalmologe; 2014 May; 111(5):410. PubMed ID: 24959646
[No Abstract] [Full Text] [Related]
3. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of matrix metalloproteinase-9 for the treatment of dry eye syndrome; a review study.
Shoari A; Kanavi MR; Rasaee MJ
Exp Eye Res; 2021 Apr; 205():108523. PubMed ID: 33662353
[TBL] [Abstract][Full Text] [Related]
5. Effects of Quercetin in a Mouse Model of Experimental Dry Eye.
Oh HN; Kim CE; Lee JH; Yang JW
Cornea; 2015 Sep; 34(9):1130-6. PubMed ID: 26203745
[TBL] [Abstract][Full Text] [Related]
6. New in Vivo Compatible Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitors.
Beutel B; Song J; Konken CP; Korpos E; Schinor B; Gerwien H; Vidyadharan R; Burmeister M; Li L; Haufe G; Sorokin L
Bioconjug Chem; 2018 Nov; 29(11):3715-3725. PubMed ID: 30277751
[TBL] [Abstract][Full Text] [Related]
7. Effects of chondrocyte-derived extracellular matrix in a dry eye mouse model.
Kim CE; Oh HN; Lee JH; Yang JW
Mol Vis; 2015; 21():1210-23. PubMed ID: 26604661
[TBL] [Abstract][Full Text] [Related]
8. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model.
Lekhanont K; Leyngold IM; Suwan-Apichon O; Rangsin R; Chuck RS
Cornea; 2007 Jan; 26(1):84-9. PubMed ID: 17198019
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye.
Sambursky R; Davitt WF; Latkany R; Tauber S; Starr C; Friedberg M; Dirks MS; McDonald M
JAMA Ophthalmol; 2013 Jan; 131(1):24-8. PubMed ID: 23307206
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Effect of RSH-12, a Novel Selective MMP-9 Inhibitor Peptide, in the Treatment of Experimentally Induced Dry Eye Model.
Shoari A; Rasaee MJ; Rezaei Kanavi M; Afsar Aski S; Tooyserkani R
Curr Eye Res; 2021 Jan; 46(1):7-13. PubMed ID: 32567381
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of epidermal growth factor on benzalkonium chloride-induced dry eye in a mouse model.
Xiao X; He H; Lin Z; Luo P; He H; Zhou T; Zhou Y; Liu Z
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):191-7. PubMed ID: 22159022
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye.
De Paiva CS; Corrales RM; Villarreal AL; Farley WJ; Li DQ; Stern ME; Pflugfelder SC
Exp Eye Res; 2006 Sep; 83(3):526-35. PubMed ID: 16643899
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic effect of DA-6034 on ocular inflammation via suppression of MMP-9 and inflammatory cytokines and activation of the MAPK signaling pathway in an experimental dry eye model.
Seo MJ; Kim JM; Lee MJ; Sohn YS; Kang KK; Yoo M
Curr Eye Res; 2010 Feb; 35(2):165-75. PubMed ID: 20136427
[TBL] [Abstract][Full Text] [Related]
14. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease.
Solomon A; Dursun D; Liu Z; Xie Y; Macri A; Pflugfelder SC
Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2283-92. PubMed ID: 11527941
[TBL] [Abstract][Full Text] [Related]
15. Selenium compound protects corneal epithelium against oxidative stress.
Higuchi A; Inoue H; Kawakita T; Ogishima T; Tsubota K
PLoS One; 2012; 7(9):e45612. PubMed ID: 23049824
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Suwan-apichon O; Rizen M; Rangsin R; Herretes S; Reyes JM; Lekhanont K; Chuck RS
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):133-9. PubMed ID: 16384954
[TBL] [Abstract][Full Text] [Related]
17. MMP-8 Is Critical for Dexamethasone Therapy in Alkali-Burned Corneas Under Dry Eye Conditions.
Bian F; Wang C; Tukler-Henriksson J; Pflugfelder SC; Camodeca C; Nuti E; Rossello A; Li DQ; de Paiva CS
J Cell Physiol; 2016 Nov; 231(11):2506-16. PubMed ID: 26923552
[TBL] [Abstract][Full Text] [Related]
18. New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.
Behrends M; Wagner S; Kopka K; Schober O; Schäfers M; Kumbhar S; Waller M; Haufe G
Bioorg Med Chem; 2015 Jul; 23(13):3809-18. PubMed ID: 25921268
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of osmoprotectants on prevention and treatment of murine dry eye.
Chen W; Zhang X; Li J; Wang Y; Chen Q; Hou C; Garrett Q
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6287-97. PubMed ID: 23970467
[TBL] [Abstract][Full Text] [Related]
20. Experimentally induced dry eye produces ocular surface inflammation and epithelial disease.
Dursun D; Wang M; Monroy D; Li DQ; Lokeshwar BL; Stern M; Pflugfelder SC
Adv Exp Med Biol; 2002; 506(Pt A):647-55. PubMed ID: 12613973
[No Abstract] [Full Text] [Related]
[Next] [New Search]
